The efficacy and safety of the combination of axitinib and pembrolizumab‐activated autologous DC‐CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study-Reference-Cited by-同舟云学术

The efficacy and safety of the combination of axitinib and pembrolizumab‐activated autologous DC‐CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study

Published:2021-01 Issue:3 Volume:10 Page:
ISSN:2050-0068
Container-title:Clinical & Translational Immunology
language:en
Short-container-title:Clin Transl Immunol

Author:

Song Meng‐Jia¹²^ORCID,Pan Qiu‐Zhong¹²,Ding Ya¹²,Zeng Jianxiong¹²,Dong Pei¹³,Zhao Jing‐Jing¹²,Tang Yan¹²,Li Jingjing¹²,Zhang Zhiling¹³,He Junyi¹²,Yang Jieying¹²,Huang Yue¹²,Peng Ruiqing¹²,Wang Qi‐Jing¹²,Gu Jia‐Mei¹²,He Jia¹²,Li Yong‐Qiang¹²,Chen Shi‐Ping¹²,Huang Rongxing¹²,Zhou Zi‐Qi¹²,Yang Chaopin¹²,Han Yulong¹²,Chen Hao¹²,Liu Heping⁴,Xia Shangzhou⁴,Wan Yang⁴,Weng De‐Sheng¹²,Xia Liming⁴,Zhou Fang‐Jian¹³,Xia Jian‐Chuan¹²

Affiliation:

1. Collaborative Innovation Center for Cancer Medicine State Key Laboratory of Oncology in South China Sun Yat‐sen University Cancer Center Guangzhou China

2. Department of Biotherapy Sun Yat‐sen University Cancer Center Guangzhou China

3. Department of Urology Sun Yat‐sen University Cancer Center Guangzhou China

4. Guangzhou Yiyang Bio‐technology Co., Ltd Guangzhou China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

General Nursing,Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cti2.1257

Reference50 articles.